You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
|
|---|---|
| Published in |
Journal of Hematology & Oncology, May 2017
|
| DOI | 10.1186/s13045-017-0473-4 |
| Pubmed ID | |
| Authors |
Prabhsimranjot Singh, Sudhamshi Toom, Yiwu Huang |
| Abstract |
Targeted therapy and immunotherapy have revolutionized treatment of various cancers in the past decade. Despite targeted therapy with trastuzumab in Her2-positive gastric cancer patients, survival has been dismal, mostly due to disease progression and toxicity related to the treatments. One area of active development is looking for ideal monoclonal antibodies (IMAB) specific to the proteins only on the tumor and hence avoiding unnecessary side effects. Claudin proteins with isoform 2 are one such protein, specific for several cancers, particularly gastric cancer and its metastases, leading to the development of anti-claudin 18.2 specific antibody, claudiximab. This review will highlight the latest development of claudiximab as first in class IMAB for the treatment of gastric cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 152 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 152 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 32 | 21% |
| Other | 17 | 11% |
| Student > Ph. D. Student | 16 | 11% |
| Student > Master | 13 | 9% |
| Student > Bachelor | 11 | 7% |
| Other | 16 | 11% |
| Unknown | 47 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 31 | 20% |
| Medicine and Dentistry | 26 | 17% |
| Immunology and Microbiology | 12 | 8% |
| Agricultural and Biological Sciences | 10 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 6% |
| Other | 12 | 8% |
| Unknown | 52 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2024.
All research outputs
#2,115,337
of 24,679,965 outputs
Outputs from Journal of Hematology & Oncology
#171
of 1,267 outputs
Outputs of similar age
#39,524
of 314,981 outputs
Outputs of similar age from Journal of Hematology & Oncology
#6
of 49 outputs
Altmetric has tracked 24,679,965 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,267 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.6. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,981 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.